Clinical Trials Logo

Clinical Trial Summary

This pilot and feasibility study is focusing on patients presenting with suspected malignancies of the lung and pleura who are considered to be good surgical candidates. The primary end-point of the study is to determine the sensitivity of OTL uptake and expression in identifying those lung and pleural nodules when excited by an imaging probe. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, two to three hours, prior to surgery.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • a Diagnosis of Any Resectable Lung or Pleural Nodule

NCT number NCT02769156
Study type Interventional
Source Abramson Cancer Center of the University of Pennsylvania
Contact Sunil Singhal, MD
Phone 855-216-0098
Email PennCancerTrials@emergingmed.com
Status Recruiting
Phase Phase 1
Start date June 2015
Completion date December 2024